5-Amino-1MQ: The NNMT Inhibitor With No Human Data
5-Amino-1MQ blocks NNMT, raising NAD+ and suppressing fat storage in mice. The rodent evidence is strong and consistent. Human trials: zero. What that means in practice.
Supplements
Berberine vs Semaglutide: What the Evidence Actually Shows. Part of the Supplements library by Dr. med. univ. Julian Douwes
5-Amino-1MQ blocks NNMT, raising NAD+ and suppressing fat storage in mice. The rodent evidence is strong and consistent. Human trials: zero. What that means in practice.
Adipotide kills the blood supply of white fat. It reversed obesity in mice and monkeys, caused dose-limiting kidney changes, and its only human trial stopped after four patients.
AICAR activates AMPK and improved endurance in untrained mice. In humans it has been given to thousands of cardiac surgery patients — at gram doses — and failed its definitive trial.
Native GLP-1 7-36 amide is the real human incretin hormone — and it lasts about two minutes in blood. What the infusion trials showed and why analogues replaced it.
HGH Fragment 176-191 is sold as a fat-loss peptide and is not the same molecule as AOD-9604. What the 1978–2001 rodent work showed, the protocols people use, and the honest verdict.
Liraglutide (Saxenda, Victoza) was the first GLP-1 approved for obesity. What SCALE and LEADER showed, the full titration schedule, and where a daily shot still wins.
Mazdutide (Xinermei, IBI362) is a GLP-1/glucagon dual agonist approved in China. GLORY-1, GLORY-2 and US phase 2 results, dosing to 9 mg, and how it differs from tirzepatide.
Tirzepatide (Mounjaro, Zepbound) in depth: 21% weight loss in SURMOUNT-1, randomised outcome data in sleep apnoea, HFpEF and MASH, the full titration schedule and the trade-offs.
A physician's evidence-based guide to black seed oil and thymoquinone—dosing, mechanisms, clinical uses in MCAS, autoimmunity, and metabolic health, plus who should avoid it.
Evidence-based humanin peptide dosing guide covering optimal doses, injection frequency, cycling, routes of administration, and patient-specific titration strategies.
Berberine inhibits CYP3A4 and P-gp, creating clinically significant interactions with statins, warfarin, cyclosporine, and more. A physician's evidence-based guide.
How rapamycin targets mTOR in the liver to reverse diet-induced metabolic stress, protect hepatocytes, and what this means for longevity patients with metabolic risk.
Evidence-based MOTS-c dosage guide covering subcutaneous injection protocols, cycling schedules, stacking strategies, and who benefits most from this mitochondrial peptide.
VK2735 is a dual GIP/GLP-1 agonist from Viking Therapeutics, in Phase 3 as a weekly injection and tested in Phase 2 as a daily tablet. What the data show.
A clinical comparison of GLP-1, dual GIP/GLP-1, and triple GIP/GLP-1/glucagon agonists — efficacy, weight loss, muscle preservation, and who qualifies in 2026.
Fat-soluble thiamine that crosses cell membranes conventional B1 cannot. How benfotiamine repairs peripheral nerves, reduces oxidative stress, and supports recovery in Lyme, diabetes, and post-COVID neuropathy.
A physician's evidence-based comparison of berberine and semaglutide for blood sugar control and weight loss — mechanisms, efficacy, safety, and who benefits most.
What the science says about the fasting mimicking diet, ProLon, autophagy, and whether a 5-day caloric restriction cycle belongs in a longevity protocol.
Learn how CGM devices reveal hidden glucose patterns, guide nutrition decisions, and predict metabolic disease years before conventional labs catch it.
Akkermansia muciniphila strengthens gut barrier integrity, improves metabolic markers, and predicts immunotherapy response. A clinical review of supplementation evidence.
MOTS-c is a mitochondria-encoded peptide that activates AMPK, improves insulin sensitivity, and may extend healthspan. A physician's clinical overview.
Dr. Douwes breaks down how berberine lowers blood sugar, what the clinical trials actually show, and the dosing protocol he uses in practice.